Natera enrolls melanoma trial patients. Natera stock gains 2.75 percent

Published on 10/09/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays raised its target to USD 475.00 on October 7, 2026. Natera stock costs EUR 358.20 after EUR 348.60, plus 2.75 percent on October 9, 2026.

Key points in brief

Natera announced first patient enrollment in a Signatera-guided melanoma trial on October 7, 2026.
Barclays raised its Natera target from USD 340.00 to USD 475.00 and kept an Overweight rating.
Natera stock was trading at EUR 358.20 at Lang & Schwarz on October 9, 2026, up 2.75 percent versus EUR 348.60.
Natera reported USD 752.75 million in second-quarter 2026 revenue, up 37.70 percent year over year.
The next earnings date listed for Natera is November 11, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) announced first patient enrollment in a Signatera-guided melanoma trial on October 7, 2026, according to StockTitan. Natera stock was trading at EUR 358.20 at Lang & Schwarz on October 9, 2026 at 4:38 p.m. CEST, up 2.75 percent versus the EUR 348.60 prior close.

Barclays lifts target to USD 475

Aktiencheck reported on October 7, 2026 that Barclays raised its Natera target from USD 340.00 to USD 475.00 and retained an Overweight rating. The note also described a demanding setup because valuations already reflected positive surprises in third-quarter and following-year estimates.

The target increase puts Barclays' valuation marker USD 115.00 above its previous level, a 33.82 percent increase calculated from USD 340.00. That comparison matters because the same note combines the higher target with a warning that expectations for future results are already elevated.

What does the trial add?

The melanoma study is designed to test whether Signatera can identify molecular residual disease before progression appears on imaging. Patients who remain Signatera-positive after six weeks of first-line treatment are randomized between continuing therapy and intensifying treatment, with progression-free survival as the primary endpoint, according to StockTitan.

Three milestones frame the update

On September 22, 2026, Natera said Japan approved Signatera as a companion diagnostic for muscle-invasive bladder cancer, with a commercial launch planned for the first half of 2027, according to StockTitan. On October 6, 2026, Natera reported ASTRO data showing 100.00 percent sensitivity and 97.00 percent specificity in a real-world rectal-cancer study, according to Natera. On October 7, 2026, the melanoma program reached first-patient enrollment, the current event in the sequence.

Revenue growth meets a November date

Natera generated USD 752.75 million in revenue in the second quarter of 2026, up 37.70 percent from the year-ago quarter, and management raised fiscal 2026 revenue guidance to USD 2.85 billion-USD 2.91 billion, according to Investing.com. The same source lists November 11, 2026 as the next earnings date.

Stock remains below its yearly high

Natera's market capitalization was USD 57.3 billion as of October 9, 2026, while its Nasdaq 52-week range was USD 167.99 to USD 437.41. The current euro quotation therefore sits in a market context shaped by rapid revenue growth, expanding Signatera use and high expectations for upcoming results.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.